Highlights
- Market Cap
- £2.71M
- Enterprise Value
- £467.34K
- EPS (TTM)
- -£0.04
- Total Revenue (TTM)
- £5.51M
- Gross Profit (TTM)
- £2.66M
- EBITDA (TTM)
- -£10.55M
- Year Range
- £0.01 - £0.06
- ROA (TTM)
- -258.52%
- ROE (TTM)
- -409.76%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in Genincode PLC, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Different Benchmark Currency
GENI.L is traded in GBp, while the ^GSPC benchmark is in USD. To make them comparable, the benchmark values have been converted to GBp using the latest available exchange rates.
Returns By Period
Genincode PLC (GENI.L) has returned -54.58% so far this year and -61.75% over the past 12 months.
Genincode PLC
- 1D
- 6.34%
- 1M
- -3.11%
- YTD
- -54.58%
- 6M
- -69.72%
- 1Y
- -61.75%
- 3Y*
- -59.98%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.61%
- 1M
- -3.22%
- YTD
- -2.82%
- 6M
- -0.72%
- 1Y
- 13.66%
- 3Y*
- 14.01%
- 5Y*
- 11.18%
- 10Y*
- 12.98%
Monthly Returns
Based on dividend-adjusted daily data since Jul 22, 2021, GENI.L's average daily return is -0.09%, while the average monthly return is -2.34%.
Historically, 26% of months were positive and 74% were negative. The best month was Sep 2025 with a return of +157.1%, while the worst month was Apr 2025 at -50.9%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 11 months.
On a daily basis, GENI.L closed higher 12% of trading days. The best single day was Sep 16, 2025 with a return of +147.7%, while the worst single day was Apr 30, 2025 at -40.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -50.42% | -5.46% | -3.11% | -54.58% | |||||||||
| 2025 | 9.21% | -14.46% | -19.72% | -50.88% | 10.71% | 45.16% | -20.00% | -22.22% | 157.14% | -19.44% | -25.86% | 11.63% | -36.84% |
| 2024 | -19.05% | -9.41% | 78.57% | 5.45% | 6.90% | -12.90% | -3.70% | 3.85% | -22.22% | -20.95% | 2.41% | -10.59% | -27.62% |
| 2023 | 100.00% | 41.94% | -22.73% | -14.71% | -6.90% | -11.11% | -3.33% | 7.76% | -22.00% | -20.51% | -20.97% | -14.29% | -32.26% |
| 2022 | -12.31% | -7.02% | -0.94% | -2.10% | -20.23% | -7.32% | -11.84% | 4.48% | 0.00% | -26.29% | -10.85% | -32.61% | -76.15% |
| 2021 | -18.12% | 27.87% | -13.48% | -1.30% | -4.61% | -10.34% | -23.53% |
Benchmark Metrics
Genincode PLC has an annualized alpha of -20.97%, beta of 0.03, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 23, 2021.
- This stock participated in 310.94% of S&P 500 Index downside but only 12.51% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.03 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -20.97%
- Beta
- 0.03
- R²
- 0.00
- Upside Capture
- 12.51%
- Downside Capture
- 310.94%
Return for Risk
Risk / Return Rank
GENI.L ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Genincode PLC (GENI.L) and compare them to a chosen benchmark (S&P 500 Index).
| GENI.L | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.33 | 0.73 | -1.06 |
Sortino ratioReturn per unit of downside risk | 0.36 | 1.14 | -0.78 |
Omega ratioGain probability vs. loss probability | 1.06 | 1.18 | -0.12 |
Calmar ratioReturn relative to maximum drawdown | -0.74 | 1.24 | -1.98 |
Martin ratioReturn relative to average drawdown | -1.25 | 4.87 | -6.12 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore GENI.L risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Genincode PLC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Genincode PLC was 97.80%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Genincode PLC drawdown is 97.66%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.8% | Aug 27, 2021 | 1158 | Mar 30, 2026 | — | — | — |
| -18.12% | Jul 23, 2021 | 5 | Jul 29, 2021 | 7 | Aug 9, 2021 | 12 |
| -6.52% | Aug 12, 2021 | 8 | Aug 23, 2021 | 3 | Aug 26, 2021 | 11 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Genincode PLC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Genincode PLC is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GENI.L relative to other companies in the Diagnostics & Research industry. Currently, GENI.L has a P/S ratio of 0.5. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GENI.L in comparison with other companies in the Diagnostics & Research industry. Currently, GENI.L has a P/B value of 1.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |